Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study

South Med J. 2003 Nov;96(11):1128-32. doi: 10.1097/01.SMJ.0000084294.77504.4B.

Abstract

Background: We sought to assess whether proton pump inhibitor (PPI) therapy of gastroesophageal reflux disease (GERD) in patients with lone paroxysmal atrial fibrillation (PAF) leads to a reduction of PAF-related symptoms.

Methods: The records of patients with reflux esophagitis were screened for the diagnosis of lone PAF. All patients with reflux esophagitis and lone PAF were invited for a follow-up visit, at which PAF- and GERD-related symptoms, medication, and electrocardiogram were recorded.

Results: Among 89 patients, 18 (6 women, aged 39-69 years) had lone PAF. Decrease or disappearance of at least one PAF-related symptom occurred in 14 of 18 patients (78%) after PPI therapy. In two of the remaining four patients, GERD-related symptoms persisted. Antiarrhythmic drugs were discontinued in five patients, and none had to be increased in dosage or newly prescribed. The electrocardiogram showed sinus rhythm in all patients.

Conclusion: In lone PAF, GERD should be investigated as a potential pathogenetic mechanism. PPI therapy reduces not only GERD-related but also PAF-related symptoms.

MeSH terms

  • Adult
  • Aged
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / etiology*
  • Female
  • Gastroesophageal Reflux / complications*
  • Gastroesophageal Reflux / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Proton Pump Inhibitors
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors